Curated gurus reporting this holding
A curated subset of well-known investors — not the full institutional ownership.
- Duquesne Family Office1,894,450주2026-06-30 · 증감 0주
- Coatue Management9,819,992주2026-06-30 · 증감 0주
Caris Life Sciences, Inc. Common Stock company information
카리스 라이프 사이언시스NASDAQ:CAI · Nasdaq$27.10-1.29%
2026-10-07 close · prelimCaris Life Sciences, Inc. Common Stock's company information is shown as of 2026-10-07. It is a security listed on Nasdaq, ticker CAI. There are 14 published related companies.
About this company
Caris Life Sciences, Inc. Common Stock last closed at $27.10 (-1.29%) on 2026-10-07. Listed on Nasdaq.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- Arbor Realty Trust REITUSABR-US →
Shared holders: Coatue Management
- ArganUSAGX-US →
Shared holders: Coatue Management
- Applied MaterialUSAMAT-US →
Shared holders: Coatue Management
- AMC Entertainment Holdings Class AUSAMC-US →
Shared holders: Coatue Management
- Advanced Micro DevicesUSAMD-US →
Shared holders: Coatue Management
- Amazon ComUSAMZN-US →
Shared holders: Coatue Management
- AppLovin Class AUSAPP-US →
Shared holders: Coatue Management
- ASML Holding NV ADRUSASML-US →
Shared holders: Coatue Management
Suppliers, competitors and related stocks
- Tempus AICompetitor
액체생검·AI 기반 정밀의료 분석 분야 경쟁
- Guardant HealthCompetitor
암 진단용 액체생검/동반진단의 대표 경쟁사
- NateraCompetitor
분자진단·암 검사를 포함한 정밀의료 경쟁사
- Foundation MedicineCompetitor
종양 유전체 프로파일링과 동반진단에서 경쟁
- IlluminaSupplier
NGS 기반 유전체 분석의 핵심 장비·시퀀싱 공급사
- Thermo Fisher ScientificSupplier
분자진단·실험실 장비와 시약의 주요 공급사
- Agilent TechnologiesSupplier
유전체·진단 연구용 분석 장비와 시약 공급사
- Exact SciencesCompetitor
암 조기진단 및 분자진단 검사 경쟁사
- BioNTechRelated theme
정밀의료·동반진단과 연관된 생명공학 테마
- Merck & Co.Customer
종양학 신약 개발에서 동반진단 협력 가능성이 큰 제약사
- Bristol Myers SquibbCustomer
암 치료제 개발과 바이오마커 기반 환자선별 협력 대상
- AstraZenecaCustomer
종양학 파이프라인에서 동반진단·환자군 선별 수요가 큰 제약사
- PfizerCustomer
정밀의료 기반 임상개발과 바이오마커 검사 수요가 있는 제약사
- Roche Holding AGCompetitor
진단·종양학 검사 및 정밀의료 플랫폼 경쟁사
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $1M(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Quantus Signal · live data · not investment advice · Privacy Policy